Abstract
This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.
MeSH terms
-
Amantadine / economics
-
Amantadine / therapeutic use
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / economics*
-
Antiparkinson Agents / therapeutic use*
-
Catechol O-Methyltransferase Inhibitors
-
Combined Modality Therapy
-
Deep Brain Stimulation* / economics
-
Drug Costs
-
Electrodes, Implanted
-
Enzyme Inhibitors / economics
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Levodopa / economics
-
Levodopa / therapeutic use
-
Models, Economic
-
Neurosurgical Procedures
-
Parkinson Disease / drug therapy
-
Parkinson Disease / economics*
-
Parkinson Disease / therapy*
-
Retrospective Studies
-
Subthalamic Nucleus / physiology*
Substances
-
Antiparkinson Agents
-
Catechol O-Methyltransferase Inhibitors
-
Enzyme Inhibitors
-
Levodopa
-
Amantadine